Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user is questioning if Aveda composition oil promotes hair growth or blocks it, listing its ingredients. They are experiencing severe hair thinning and are unsure if they should continue using the product.

The user reported high testosterone and estradiol levels within range, but unexpectedly high DHT levels after using finasteride and dutasteride for hair loss. Another person suggested the dutasteride might be fake or a bad batch and recommended using the branded Avodart.

Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

The conversation is about managing potential gynecomastia from finasteride use. The user considers using an aromatase inhibitor and plans to check hormone levels.

A user is seeking information on clinics in Toronto offering dutasteride mesotherapy as an alternative to oral dutasteride while trying to conceive. They are looking for recommendations and information.

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.

Finasteride and dutasteride are not considered safe during pregnancy, with some users suggesting caution and others sharing personal experiences of no issues. The general consensus is to avoid these medications during pregnancy to prevent any potential risks.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

A 23-year-old with hair loss uses finasteride, minoxidil, and other treatments, considering adding dutasteride due to hairline recession. They seek advice on dutasteride's effectiveness and sourcing.

A user shared their experience with hair loss treatments, initially using oral dutasteride (Avodart) and minoxidil, and recently switching to a topical dutasteride solution. They reported significant hair improvement over time and are hopeful about the new topical treatment.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The conversation is about switching from brand-name Avodart to generic Dutasmart for hair loss treatment, with concerns about shedding and side effects. The user also discusses using oral Minoxidil and plans to increase the dose for better results.

A user shared a two-year update on their hair loss treatment using dutasteride (0.5mg/day), minoxidil (Kirkland topical foam 2x/day), a 1.5mm derma roller every other week, and a daily multivitamin with biotin. They reported significant hair regrowth with no side effects, emphasizing the importance of consistency and a healthy lifestyle.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Dutasteride is considered safe for conception, with semen concentrations being too low to cause harm. Users discuss switching between dutasteride and finasteride, with some experiencing side effects like acne and heart issues, and advice is given to maintain a consistent treatment regimen.

Dutasteride prices have increased significantly, with some users reporting a rise from €42 to €62 for 100 pills. Shipping costs and manufacturer price hikes are contributing factors.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

A 20-year-old is experiencing severe hair loss and is considering using dutasteride and finasteride, worried about potential side effects. They feel depressed and isolated due to hair loss, and are exploring options like hair transplants and hair systems but are hesitant about faking it.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

The user experienced hair loss after initially seeing positive results from using dutasteride and oral minoxidil. They are concerned about the hair shedding and wonder if stopping a multivitamin contributed to the issue.

The user experienced increased shedding and an itchy scalp after switching from Ascend to Aurobindo finasteride. They are considering switching to dutasteride and are concerned about elevated estrogen levels and the effectiveness of adding minoxidil later.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

A 28-year-old has been using oral dutasteride 0.5 mg, topical minoxidil 5%, and Cafune shampoo for 104 days with positive results and is considering adding microneedling. No side effects from dutasteride have been reported.

A 26-year-old used high-dose dutasteride monotherapy for two years, reporting significant hair regrowth without side effects. The user avoided combining it with minoxidil due to cardiac risk concerns.

The user experienced side effects like watery semen, erection problems, and decreased libido from finasteride, which resolved after stopping it. They are considering dutasteride mesotherapy as an alternative, as advised by their dermatologist, and are concerned about potential side effects.